Markets

Aduro Doses First Patient in Phase I Study on ADU-741

An image of stocks on a display
Credit: Shutterstock photo

Aduro BioTech, Inc.ADRO announced that it has dosed the first patient in a phase I study on ADU-741 (also known as JNJ-64041809) for the treatment of patients with prostate cancer.

The open-label study will enroll patients (n=40) with metastatic castration-resistant prostate cancer.

We note that the study is being conducted by Aduro's license partner for ADU-741, Janssen Biotech, Inc., a Johnson & Johnson JNJ company. In May 2014, the companies entered a research and license agreement to collaborate on the development of the candidate for the treatment of prostate cancer. As per the terms of the agreement, Janssen has the worldwide exclusive right to research, develop, manufacture, use, sell and otherwise exploit products containing ADU-741 for any and all uses. In addition, the company is responsible for carrying out certain research and development activities on the candidate until an investigational new drug (IND) application is approved.

We remind investors that last week, Aduro announced that it has received a milestone payment from Janssen on the acceptance of an IND application for ADU-741 in the U.S. Till date, the company has received an upfront payment and milestone payments associated with both the submission and the acceptance of the IND. In addition, Aduro is eligible to receive future development, regulatory and commercialization milestone payments of up to $345.5 million and royalties on worldwide net sales.

Meanwhile, Aduro and Janssen continue to work on the development of another candidate under their collaboration. Earlier this month, a phase I study on ADU-214 was initiated for the treatment of patients with lung cancer. The study is being conducted on patients with advanced or metastatic non-small cell lung cancer.

Aduro currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector includes Anika Therapeutics Inc. ANIK and Achillion Pharmaceuticals, Inc. ACHN both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

ADURO BIOTECH (ADRO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK JNJ KDNY

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More